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Corticosteroids have been in use for decades and are one of the most prescribed 
drugs in all specialties of medicine. Jerome Posner, in his classic textbook “Neurological 
Complications of Cancer,” refers to corticosteroids as widely used drugs in neuro-
oncology leading to a remarkable decline in perioperative mortality and morbidity 
rates. Being the most powerful class of tumor-induced-edema reducing agents, they are 
adjuvant to chemotherapy and are also known to reduce the risk of encephalopathy and 
other associated neurological deficits in patients undergoing radiation therapy. They 
have been widely used in higher-than-normal doses in the management of pathologic, 
immunological, and inflammatory conditions and various other diseases. Novel insights 
into the mechanisms of action of corticosteroids and their effects on cancer patients are 
extensively being studied. While substantial clinical improvements can be seen in cancer 
patients, corticosteroids are also associated with adverse and well-characterized side 
effects leading to immediate as well as long-term complications in patients. This chapter 
reviews the clinical aspects of corticosteroid therapy used in neuro-oncological condi-
tions and its effects on peritumoral edema. Although there is currently insufficient infor-
mation on appropriate use, in most cases, corticosteroids are used in a supraphysiological 
and pharmacological manner to minimize the symptoms of cerebral edema. Due to 
limited clinical studies and evident side effects presenting synonymously with corti-
costeroid therapy, the emerging role of steroid-sparing drugs such as corticotrophin-
releasing factors, tyrosine kinase inhibitors, and VEGF inhibitors will also be discussed.
Keywords: Neuro-oncology, brain tumor, cerebral edema, corticosteroid therapy, 
dexamethasone, bevacizumab
1. Introduction
Corticosteroids are synthetic analogs of a class of naturally synthesized hormone 
molecules in the adrenal cortex that act as biological mediators. These hormones 
play a vital role in regulating essential bodily processes such as metabolism, inflam-
mation, response to stress, and electrolyte balance.
Corticosteroids have been classified based on major effects exhibited by 
them into glucocorticoids and mineralocorticoids. Glucocorticoids provide 
anti-inflammatory responses by suppressing inflammation and immunity, exert 
vasoconstrictive, and are responsible for the breakdown of fats, proteins, and 
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carbohydrates. Cortisol is a physiological mediator well-characterized to exhibit 
glucocorticoid effects in humans. Mineralocorticoids exhibit salt-retaining and 
electrolyte-balancing properties. A prominent hormone, aldosterone, projects 
the strongest mineralocorticoid activity. The pioneering of corticosteroids (such 
as dexamethasone, prednisolone, prednisone) has revolutionized the treatment 
approaches in the field of clinical oncology [1]. They mimic the action of naturally 
occurring hormones, are currently one of the most prescribed drugs worldwide, and 
can be used to treat several conditions such as infections, inflammatory disorders, 
allergic and autoimmune diseases, shock, lowering of excessive blood calcium levels, 
hypoglycemia, suppression of excess secretion from the adrenal cortex, prevention 
of graft rejection, neurological disorders, hematologic disorders, skin disorders, and 
corticosteroid replacement therapy [2, 3].
Steroids administered to brain tumor patients do not directly treat the tumor 
but are targeted to reduce edema surrounding the tumor (induced by the tumor 
itself or its treatment) thereby the mass effect and lymphoma in the central nervous 
system, prevent or alleviate the symptoms of nausea, vomiting and headache post-
chemotherapy and temporarily improve other associated neurological symptoms 
[1]. They can cross the blood–brain barrier and act as analgesic agents by inhibiting 
the synthesis of prostaglandins thereby reducing inflammation and tissue edema is 
resolved by decreasing vascular permeability. Sustained use in high doses requires 
close monitoring to prevent and manage its side effects and intervene if other 
complications arise.
2. Traditional approaches to steroid therapy in brain tumor patients
The introduction of steroids, 50 years ago, revolutionized therapeutic 
approaches in Clinical oncology. The first use of cortisone to treat cerebral edema 
developed in patients post neurosurgery was accomplished by Ingraham in 1952 
[4]. About five years later, Kofman pioneered the use of prednisone for peritumoral 
edema induced in patients with intracranial malignancies [5]. Dexamethasone, syn-
thesized in 1958, is based on Galcich’s experimental demonstration of brain tumor 
inhibition upon administering large doses of dexamethasone [6]. Its pioneering 
fundamentally changed the course of corticosteroid therapy in cancer patients and 
to date has been the most commendable drug due to its conducive effects in alleviat-
ing symptoms of tumor-induced cerebral edema and offers benefits of low sodium 
and water retention index thereby reducing the risk of electrolyte imbalance, low 
mineralocorticoid effect, and high glucocorticoid potency [1, 7, 8].
With further advancements, exhibited antineoplastic effects of dexamethasone, 
prednisone, prednisolone, and methylprednisolone against hematologic malignan-
cies, their antiedema, and anti-lymphoma properties were known [9]. The adminis-
tration of steroids has proved beneficial in rapidly relieving symptoms, minimizing 
tumor-associated pain, nausea, and vomiting, and ameliorate appetite in tumor 
patients [10]. Its advantageous characteristics have found immense clinical applica-
tions such as in treating patients with carcinomatous meningitis and lymphoma in 
the central nervous system [11].
3. Molecular mechanisms
Corticosteroids are the mainstay of treatment for neuro-oncological conditions, 
and they undergo various molecular mechanisms at the cellular level to give desired 
clinical results. These mechanisms are complex and distinct and with currently 
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limited evidence, are divided into genomic and non-genomic. The consensus is that 
the genetic level, effects such as an increased rate of transcription known as trans-
activation, a transrepression-a process in which one protein represses the activity 
of the second protein, and post-translational regulation i.e., controlling the levels 
of active protein, can be seen, constituting the genomic mechanism, and producing 
anti-inflammatory effects. Activating a cascade of signaling pathways constitutes 
the non-genomic effects. These mechanisms mediate several side-effects, such as 
diabetes and glaucoma due to transactivation while suppression of hypothalamic–
adrenal–pituitary axis due to transactivation. Both transactivation and transrepres-
sion seem to be involved in osteoporosis. Glucocorticoids bind to complementary 
cytoplasmic receptors upon diffusion through the plasma membrane. The binding 
of this free glucocorticoid receptor leads to the release of a heat-shock protein 
90 kDa which in turn exposes two nuclear localization signals responsible for 
facilitating the movement of the glucocorticoid–receptor complex into the nucleus 
[12]. Specific DNA (deoxyribonucleic acid) elements called glucocorticoid response 
elements (GRE) regulate the transcription of nuclear DNA. Synthesis of several 
cytokines and chemokines involved in regulating inflammatory reactions such as 
eotaxin and lipocortin 1 is suppressed by glucocorticoids at the level of transcription 
[13]. The interaction of glucocorticoids with other transcription factors such as p53 
indirectly influences their activity on their target genes [14]. The production of 
proinflammatory cytokines and chemokines is controlled by transcription factors 
such as NF-KB, CRE-binding proteins, among others, and leads to activation of 
inflammatory pathways. Therefore, inhibiting these transcription factors induces 
anti-inflammatory responses [12, 15]. To summarize the mechanism: corticoste-
roids bind to intracellular cytoplasmic receptors upon crossing the plasma mem-
brane and form the steroid–receptor complex. Consequently, the movement of the 
steroid-receptor complex into the nucleus directly influences the transcription of 
genes and upon interaction with other transcription factors, a non-transcriptional 
regulation of other signaling cascades is mediated.
4. Vasogenic edema and Antiedema property of corticosteroids
The use of corticosteroids for the management of malignant brain tumors and 
symptomatic peritumoral edema was recognized several decades ago [3]. They are 
frequently prescribed to reduce the increased intracranial pressure caused due to 
peritumoral fluid accumulation. Although edema occurs in patients with malignant 
lesions but is also evident in cases of benign tumors such as meningiomas [16, 17]. 
A disruption in the blood–brain barrier leads to the flow of fluid into extracellular 
spaces of brain parenchyma resulting in vasogenic edema. This disruption results 
in increased permeability of the BBB primarily due to the opening of the inter-
endothelial tight junctions and increased endothelial pinocytosis and endothelial 
fenestrations [18, 19]. An insufficient number of normal astrocytes, responsible 
for producing factors that are required for the formation of normal BBB, results 
in defects in endothelial tight junctions, production of cytokines such as vascular 
endothelial growth factor (VEGF) [20], and hepatocyte growth factor [21] by both 
benign and malignant brain tumors and increase tumor vessel permeability [22]. 
The suggested mechanism of corticosteroids is a reduction in permeability of tumor 
vessels by upregulation of genes and molecules such as occludin, a tight junction 
component in endothelial cells [23], and by dephosphorylating occludin and 
another TJ component, zona occludens (ZO1) [24]. Another mechanism of influ-
encing the endothelial permeability is by non-transcriptional regulation of capillar-
ies that involves rearranging and attachment of vascular endothelial (VE)-cadherin 
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to the cytoskeleton [25]. The permeability of the blood–brain barrier is decreased 
upon steroid administration and this limits the extravasation of fluids [26, 27].
5. Treatment of Lymphomatous neoplasms
Steroids are frequently prescribed in patients with primary lymphoma in the 
central nervous system or in cases of secondary lymphomatous neoplasms where 
they rapidly respond by promoting cell cycle arrest and cell death by the mecha-
nism of apoptosis in a p38 mitogen-activated protein kinase (MAPK) dependent 
manner in B and T cells [27–29]. Steroids are administered during the initial stages 
along with chemotherapy and the clinical and radiographic response can be rapid in 
cases of lymphoma and inflammatory conditions. Some preclinical studies suggest 
that proliferation of some glioma cells may reduce upon dexamethasone exposure 
[30]. On the other hand, certain reports suggest that steroids have no effect or 
stimulate the growth of glioma cells [31, 32]. Effects of steroids can be transient and 
require chemotherapy or irradiation to prevent the recurrence of the tumor [33]. 
Furthermore, there is no significant clinical evidence so far that proves the role of 
steroids in the growth inhibition of gliomas or metastasis in humans.
6. Anti-emetic properties
Steroids are administered either singly or in combination with 5HT-3 receptor 
antagonists, neurokinin-1 receptor antagonists, and aprepitant for the prophylaxis 
and the treatment of chemotherapy-induced nausea and vomiting and to man-
age subsequent symptoms of dehydration and electrolyte imbalance [34]. Steroid 
administration leads to a reduced release of serotonin from hematocytes and this 
directly affects the cellular expression of its receptors, thereby preventing nausea 
and vomiting [35, 36]. The most favorable corticosteroids are methylprednisolone 
and dexamethasone in patients with moderate to high emetogenic chemotherapy.
7. Dosing and tapering
Steroid administration is adjuvant to chemotherapy and all cancer patients will 
receive steroid therapy at some point in their cancer treatment and may continue to 
receive them through surgery, chemotherapy, radiation, and prolonged use may be 
needed because of its benefits of symptomatic relief. Despite its extensive use, there 
is a lack of significant clinical evidence about the choice of drug, dose, duration, 
and tapering schemes.
Various clinical trials have been conducted that aim to assess the effects of doses 
of 8 mg versus 16 mg dexamethasone and 4 mg versus 16 mg in patients with peri-
tumoral edema. Significant clinical improvement among all groups administered 
with dexamethasone can be seen on the Karnofsky performance scale. Low doses 
of dexamethasone (4-8 mg/day) are recommended to avoid developing serious 
complications but they may require reinstitution after cessation of steroid therapy 
[37]. Whereas higher doses of dexamethasone (16 mg/day) along with osmotherapy 
(mannitol, glycerol) or surgery, may be required in adverse conditions [38]. In some 
cases, higher than usual doses may be required for headaches. Current evidence has a 
lack of information about the correlation between dose and body weight or dose and 
age. Attempts to standardize the steroid therapy regimen have remained unsuccessful 
and it is suggested that the dosage must be altered according to the specific needs of 
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the patient depending on the size of the lesion, location, mass effect, and presenting 
symptoms. It is recommended that for successful results and for preventing steroid-
associated toxicity, tapering should be considered as soon as clinically acceptable [39]. 
Interestingly, a longer duration of 23 weeks of steroid therapy is required for patients 
with a primary brain tumor as opposed to 7 weeks that is required for secondary brain 
tumors. Steroid therapy can be stopped quickly in patients that have been receiving 
it for a shorter duration, usually 10–14 days. On the other hand, careful and closely 
monitored tapering is required for patients with prolonged steroid use to avoid dec-
lination of their medical state and/or dependency or withdrawal effects and evident 
hypercortisolism. Hydrocortisone, which is commonly prescribed in 2 doses per day 
to mimic the physiological action of cortisol in patients with its deficient levels. 20 mg 
and 10 mg dose administration in the morning and afternoon, respectively, are sug-
gested for patients with remarkably high cortisol insufficiency [40].
8. Side effects
Depending on the type of drug and prescribed dose, a wide spectrum of systemic 
and neurological side effects can occur in response to corticosteroid therapy. While 
manifestations of some side effects can be seen immediately upon administration 
of corticosteroids, others may develop over time and may persist even after steroid 
therapy has been terminated, such as cataract formation and osteoporosis [1]. Most 
side effects are easily manageable, but some can be fatal. Patients considered at 
substantial risk have impaired immune systems either due to organ transplantation 
or upon undergoing chemotherapy or radiotherapy.
8.1 Systemic
Systemic side effects include a cushingoid appearance, truncal obesity, hirsut-
ism, acne, impaired wound healing, striae, nausea, anorexia, easy bruising and 
capillary fragility, immunosuppression, hypertension, increased risk of infections, 
respiratory muscle weakness, glucose intolerance, electrolyte disturbance, fluid 
retention, peripheral edema, increased appetite, gastrointestinal bleeding, growth 
retardation, cataracts, glaucoma, and visual blurring [41].
Arterial hypertension, considered as the most common side effect, occurs 
in 20% of the patients. It is usually reversible and blood pressure values attain a 
normal value upon cessation of steroid intake. For patients whose steroid therapy 
cannot be discontinued, hypertension requires symptomatic treatment. Since the 
main cause of hypertension is an abnormal increase in the volume of blood plasma 
by steroids, the preferred line of treatment is the use of diuretics [42].
8.2 Gastrointestinal
Although, no significant correlation between steroid usage and gastrointestinal 
bleeding has been found in clinical studies, yet histamine H2 antagonists and proton 
pump inhibitors are commonly prescribed to minimize the risk of gastric ulcers, 
hemorrhage, and other rare gastrointestinal problems such as pancreatitis, colon 
perforation, and fatty liver disease [43–45].
8.3 Osteoporosis
An increase in cases of developing osteoporosis and avascular necrosis is 
seen in patients receiving steroid therapy evident from the lumbar spine and hip 
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fractures [46, 47]. Although several factors can contribute to the occurrence of 
osteoporosis, yet the suggested mechanism is that due to skeletal muscles getting 
directly affected by the glucocorticoids, calcium absorption is reduced leading 
to hyperparathyroidism and a decrease in gonadal hormones. Molecular stud-
ies suggest a decrease in IGH-1 and prostaglandin E2, which are responsible for 
stimulating bone growth [48]. Administration of phenytoin and valproic acid also 
promote osteoporosis [49–51]. To prevent/manage the symptoms of osteoporosis 
calcium supplements (1500 mg/day), Vitamin D (800 international units/day) 
[48], and bisphosphonates such as alendronate and zoledronate are commonly 
prescribed [52]. Kyphoplasty may be required in patients with severe pain from 
compression fractions.
8.4 Neurological and neuropsychiatric
Common neurological side effects of corticosteroids are myopathy, visual blur-
ring, tremor, behavioral changes, headache, reduced taste and smell, and cerebral 
atrophy while rare complications include psychosis, hallucinations, neck flexors, 
dementia, seizures, dependency, epidural lipomatosis, and neuropathy.
Most pervasive yet mild neuropsychiatric effects such as anxiety, insomnia, irri-
tability, euphoria, and mood disturbances may develop in response to corticosteroid 
therapy. Adverse effects include euphoria, steroid-induced dementia, cortical atro-
phy, cognitive dysfunction, memory loss, and psychotic episodes that may occur 
but are more likely in patients with a history of psychiatric disorders. Episodes of 
seizures may relapse in patients with a history of seizure disorder. Impairment in 
physiology during the development of the brain such as hippocampal neurogenesis 
is seen in animal models administered with corticosteroids. Similarly, predniso-
lone has been shown to negatively affect verbal memory function in humans and 
long-term cognitive dysfunction is evident in children if taken in combination with 
dexamethasone. However, it can be challenging to differentiate between the mani-
festations of radiation therapy, gliomas, and the increase in levels of intracranial 
pressure with complications occurring due to corticosteroid use. Discontinuation or 
tapering is recommended for managing steroid-induced neuropsychiatric effects as 
soon as clinically acceptable. Prednisone dose must be kept lower than 40 mg/day. 
The use of Neuroleptics, valproic acid, and lithium can be considered but tricyclic 
antidepressants should be avoided as they can worsen the condition [53–57].
8.5 Myopathy
Although the pathophysiology of steroid myopathy remains unknown, yet it 
has been shown to negatively affect the quality of life in patients. Clinical studies 
suggest that steroid myopathy occurs more commonly (almost 10%) in patients 
with primary brain tumors administered with fluorinated glucocorticoids such as 
dexamethasone over the ones administered with non-fluorinated glucocorticoids, 
such as hydrocortisone or prednisone (which may not have proven to be highly 
effective in controlling cerebral edema) [58–60]. Common symptoms associated 
with steroid myopathy are a proximal weakness with normal sensation and deep 
tendon reflexes intact. Detection is made using electromyography. The probable 
mechanism of steroid myopathy can be protein synthesis inhibition, increased 
protein catabolism, and induction of the activity of glutamine synthetase [61, 62]. 
Development of muscle weakness may develop even upon administration of low 
doses over a shorter duration and may not occur in patients even with high doses 
and prolonged duration of application. Individuals without symptoms of myopathy 
may also be considered at minimal risk for developing cushingoid features and fluid 
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retention. In patients with steroid myopathy, the accepted standard of management 
is the cessation of steroids, but it may still require months for recovery to take place. 
Steroid-induced muscle wasting is demonstrated to be reduced by muscle activity 
and hence exercise and muscle therapy are recommended to alleviate the symptoms 
or reduce the risk of developing steroid myopathy [63].
8.6 Adrenal insufficiency (AI)
About 1% of patients receiving steroid therapy for the treatment of brain tumors 
develop steroid adrenal insufficiency upon sudden glucocorticoid withdrawal. The 
presenting symptoms of AI are like those of increased intracranial pressure and side 
effects of antineoplastic treatment. Management of AI is focused on hydrocortisone 
treatment and dosage is similar to that recommended for other major surgeries [64].
8.7 Diabetes
Diabetes occurs in up to 50% of steroid-treated patients and is the most common 
form of drug-induced diabetes mellitus [65]. It is already well known that cortico-
steroids, such as dexamethasone, prednisone, and hydrocortisone, cause elevations 
in blood glucose levels in both patients regardless of pre-existing diabetes. Severe 
hyperglycemia may lead to acute or severe complications, such as dehydration, 
impaired immune system and wound healing, increased risk of infection, ketoaci-
dosis, and acute hyperglycemic syndrome. According to the Joint British Diabetes 
Association (JBDA), the predisposing factors for steroid-induced hyperglycemia as 
pre-existing type 1 or 2 diabetes, obesity, family history of diabetes, among others. 
Management of steroid-induced diabetes is similar to that of regular type 2 diabe-
tes, and patients consistently showing high blood sugar levels should be treated to 
prevent long-term complications including cardiovascular and renal damage.
8.8 Steroid withdrawal
Continued corticosteroid therapy can be recommended for patients with 
advanced or terminal diseases or those in hospice care to prevent withdrawal 
symptoms including those of steroid-pseudo rheumatism, myalgia, abdominal 
pain, nausea, arthralgia, and acute adrenal insufficiency (highest risk with more 
than 6 weeks of administration). The occurrence of these complications with 
corticosteroid discontinuation would require further medication and treatment, 
aggravating the symptoms of restlessness, excessive sleepiness and can act as con-
tributing factors in relapsing of masked symptoms. It must be noted that continued 
corticosteroid administration would still require managing its side effects such as 
insomnia, hypertension, hyperglycemia, and psychotic episodes.
9. Immunological response to corticosteroids
Immunosuppression is common in response to dexamethasone causing inhibi-
tion of immune and inflammatory responses and therefore, posing a challenge for 
the development of immunotherapeutic approaches in late-stage cancer treatment. 
Risk of life-threatening fungal infections such as Pneumocystis jirovecii is elevated 
with administration of moderate to high doses [66].
While the exact mechanism is unknown, dexamethasone has been shown to 
promote apoptosis in T-lymphocytes [67], suggesting directive nature of T-cell 
positive and negative selection in the thymus by glucocorticoids, limiting the 
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activation-induced cell death during the contraction phase of an adaptive immune 
response and induction of generalized thymocyte apoptosis after polyclonal T-cell 
activation [68]. A shift in immune response towards a Th2 humoral response from a 
Th1 cellular response is induced by influencing the levels of cytokines produced by 
the lymphocytes [69]. Moreover, dexamethasone causes a reduction in the number 
of splenic and lymph node B-cells and attenuation of early B-cell progenitor pro-
liferation. Glucocorticoids also enhance the activity of macrophages and promote 
tolerance in dendritic cells thereby, exerting a potent anti-inflammatory effect [70]. 
The risk for infection may increase by steroid-induced lymphopenia but it also 
limits the number of treatment strategies applied for activating the immune system 
and boosting anti-tumor responses.
10. Immunotherapy
Novel immunotherapeutic agents such as ipilimumab are proving their potential 
efficacy in the treatment of malignant gliomas. A studied mechanism is that it tar-
gets cytotoxic T lymphocyte-associated antigen 4 and interferes with the inhibition 
of T-cell function, which subsequently translates into enhanced antitumor activity.
Current clinical developments are focusing on programmed cell death of 
immune cell receptor. Hence, clinical trials are being conducted on ipilimumab, 
that contains anti-programmed cell death-1 antibody, nivolumab for the treatment 
of glioblastoma [71, 72]. Steroids may interfere with boosting immune response 
and therefore can be counterproductive for patients delivered with vaccines. 
Accordingly, several vaccination trials restrict the use of steroids at the time of 
enrollment to select only patients with a suitable immunological profile.
11. Dexamethasone and phenytoin interactions
Phenytoin is prescribed prophylactically before surgery and in combination 
with dexamethasone during the initial stages of primary and secondary meta-
static brain tumors. Phenytoin may exert protective effects in reducing the risk 
of steroid-induced myopathy, but the mechanism remains unclear. It is suggested 
that an increase in the rate of metabolic clearance of cortisol and dexamethasone 
by phenytoin and decrease in half-life of dexamethasone by 50% and its metabolic 
conversion to hydroxyl metabolite by the action of CYP3A4, a liver enzyme could 
be the probable mechanism [73–76]. Levels of phenytoin are contrastingly altered 
upon co-administration with dexamethasone [77–79]. Hence it is difficult to 
measure levels of phenytoin in patients taking dexamethasone. Therefore, it also 
becomes extremely important to carefully monitor levels of phenytoin and tapering 
should be done as soon as the edema is successfully controlled [80].
12. Dexamethasone and chemotherapy
Administration of glucocorticoids may significantly contribute to altering the 
pharmacokinetics and may restrict the action of chemotherapeutic drugs from 
exerting the blood–brain barrier, therefore, limiting the desired effects. It was 
hypothesized by Duan et al., that hyperglycemia (occurring in response to corticoste-
roid therapy) inhibits apoptosis and therefore promotes malignant growth, causing 
proliferation of cells, speeding up the process of metastasis, and aiding resistance to 
chemotherapy. Dexamethasone exerts protective effects against apoptotic action of 
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temozolomide in glioma cells in vitro [81]. Ongoing experiments aim to determine 
the antagonizing or synergizing action of dexamethasone with chemotherapeutic 
drugs such as rapamycin and apoptotic drugs like staurosporine. Pretreatment and 
subsequent cotreatment strategies for experiments have indicated an additive effect 
of dexamethasone in combination with growth factor signaling inhibitors.
13. Alternatives to corticosteroids
Steroids have been shown to have limited effects of clinical significance and 
there are several side effects associated with it. Therefore, a need for novel anti-
angiogenic alternatives such as Bevacizumab with strong steroid-sparing, more 
effective, and less toxic characteristics, arises. It is a neutralizing antibody that 
targets a specific protein called VEGF, responsible for promoting the growth and 
spread of tumor blood vessels, therefore reducing peritumoral edema. A major 
challenge in the action of anti-VEGF is the inhibition of the action of other drugs 
administered to target the tumor since drugs similar to bevacizumab also affect 
normal blood vessels. An approval for bevacizumab is still lacking and the cost 
is a barrier. Other similar drugs are VEGF -receptor inhibitors such as cediranib, 
sorafenib, sunitinib. In the same way, tyrosine kinase inhibitors (TKIs) such as 
cediranib and cabozantinib, target vascular endothelial growth factor receptor 
2 (VEGFR-2). Similarly, drugs such as corticorelin acetate, a synthetic analog of 
corticotropin-releasing factor have been proved to reduce edema by directly acting 
on CR1 and CR2 receptors in animal models and allows higher maximal reduction 
of the dexamethasone dose compared with control-treated brain tumor patients in a 
randomized trial [82–84]. Also, patients receiving corticorelin acetate are less likely 
to be affected by myopathy or cushingoid appearance. There are still undergoing 
trials to determine its efficacy in acute and chronic peritumoral edema. The effects 
of other drugs such as boswellic acids, cyclooxygenase (COX)-2 inhibitors, and 
angiotensin-II inhibitors on brain tumors is still uncertain [85–87].
14. Glucose levels in patients administered with corticosteroids
Corticosteroid use may cause hyperglycemia in almost 20–50% of patients, 
therefore negatively affecting patient outcomes. A study conducted in Sunnybrook 
Odette Cancer Centre in Toronto and published in Annals of Palliative Medicine, 
upon categorizing patients with and without pre-existing diabetes according to the 
Canadian Diabetes Association (CDA) criterion for diagnosis of diabetes, concluded 
that the effects of corticosteroids are dose-dependent and tend to impact random 
plasma glucose (RPG) levels more than fasting plasma glucose (FPG) levels. In a 
screening conducted by Harris et al., no correlation between risk factors for diabetes 
and the patients with hyperglycemia was found, thus recommending that all cancer 
patients must be screened 4–6 hours post-administration of steroids and additional 
monitoring may not be required if normal results are obtained on individual tests 
after initial dosing. Therefore, it seems challenging to determine patients that are at 
substantial risk for developing corticosteroid-induced hyperglycemia (C-IH) and to 
prevent it if typical risk factors for diabetes do not show consistency with the develop-
ment of C-IH. Previously conducted studies concluded that C-IH is common in both 
patients with and without diabetes [odds ratio of 1.5 to 2.5 and 1.36 to 2.31 for develop-
ing glucocorticoid-induced hyperglycemia (GC-IH) in patients treated with a gluco-
corticoid (GC), respectively] and were strongly influenced by total GC dose, duration 
of use, age, and BMI (Body Mass Index) [88, 89]. Also, steroids even leading to acute 
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elevations in blood glucose levels can have significant clinical implications demanding 
early identification and management in patients both with and without diabetes.
An extensive baseline examination including medical history, body weight, 
height, and blood pressure for all patients is recommended by Liu et al., to deter-
mine risk factors or conditions that may be influenced by corticosteroid use. Before 
the commencement of corticosteroid therapy, a blood glucose test should be con-
ducted and if the initial results deviate at baseline, then home glucose monitoring 
is suggested [90]. The CDA recommends subsequent 48 hours monitoring for all 
individuals starting corticosteroid therapy and maintenance of glycemic control 
irrespective of the patient having pre-existing diabetes or not [91]. Interventions 
and continued screening may be required if the individual test results show values 
above the normal range (6–10 mmol/L). Therefore, it is extremely essential to moni-
tor patients receiving corticosteroids to prevent adverse clinical implications and 
complications that may occur in the long term in non-palliative patients. Thorough 
assessment and blood-sugar-lowering medications are recommended for patients 
with corticosteroid-induced diabetes. Whereas patients with pre-existing diabetes 
may require modifying their diabetes management regimen and consideration of 
benefits and pitfalls before moving forward with corticosteroid therapy. Monitoring 
guidelines for steroid-induced diabetes recommended by the Joint British Diabetes 
include once-a-day monitoring for patients without diabetes and the frequency of 
testing should depend on the glucose level measured. Whereas diabetic patients 
should be tested 4 times a day. Although the guideline provides a well-structured 
monitoring regime, yet extensive patient education and resources to supply all 
patients taking steroid therapy with home capillary glucose monitoring kits are 
required. A study by Zanders et al. showed that adherence to glucose-lowering drug 
treatment declines following a cancer diagnosis [92]. Introducing different forms 
of medications and treatment regimens may result in overall lower effectiveness to 
drug treatment. To summarize, it is important to note that corticosteroids are an 
essential component of standard cancer treatment, but the chronic use of corticoste-
roids may strongly influence diabetic status and negatively affect patient outcomes. 
Patients prescribed corticosteroids should be closely monitored to prevent adverse 
effects and to effectively manage in case of their occurrence. To optimize patient 
care and outcomes, it is recommended that patients receive support and monitoring 
to prevent corticosteroid-induced diabetes and complications associated with it.
15. Neuroimaging
Dramatic outcomes are seen in clinical results of over 70% of patients receiv-
ing steroid therapy for metastatic intracranial diseases with improvement in 
the enhancement of the tumor, peritumoral edema, and mass effect. Computed 
Tomography results show a linear decrease in edema volume with measure volume 
of edema reduced to one-fourth times in 2 weeks of 4 mg/day steroid administra-
tion [93]. Magnetic resonance imaging shows a decrease in 10% edema volume 
just within a week with an average reduction in the mean volume of 4.5% within 
24 hours of administering the first dose [94]. A decreased contrast enhancement 
with tumor is seen, suggesting partial restoration of the blood–brain barrier.
16. Drug of choice and recommendations
With the currently available evidence, dexamethasone is the most preferred 
drug due to its lack of mineralocorticoid activity and with its half-life being 
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36–54 hours provides longer duration relief from symptoms. There is currently 
insufficient evidence to recommend a treatment for patients with asymptomatic 
brain tumors without mass effect. Level 3 corticosteroids are recommended for 
patients with starting dose of 4–8 mg/day dexamethasone to temporarily relieve 
mild symptoms of increased ICP and edema related to mass effect and higher 
doses of 16 mg/day in divided doses, may be considered for patients with moder-
ate to severe symptoms of increased ICP due to mass effect. A one-time trial of 
corticosteroid must be conducted for a duration of less than a week and results 
should be monitored against specific goals in particular time duration and should be 
discontinued if the desired results are not achieved in that duration (for example- 
1 week). If the therapy is well suited and well-tolerated, it can be prescribed up to a 
dose of 16 mg/day (starting with minimum dose possible) for 2–3 weeks. If longer 
administration is required, then slow and carefully monitored tapering is required 
to prevent withdrawal symptoms and relapsing of initial symptoms [95–97].
17. For future investigations
Currently, there is limited information in detail about the proper use of steroids 
in neuro-oncology. Although a significant clinical improvement is seen in patients, 
an urgent need for studies addressing its dosage and toxicity exists. Future studies 
should focus on dosing and risk factors while limiting the side effects to potentially 
optimize the benefits of corticosteroid therapy.
18. Summary and discussion
Since their discovery, decades ago corticosteroids have been widely used for 
the treatment of brain tumors and have been considered one of the most powerful 
classes of tumor-induced edema reducing agents and contribute to minimizing 
associated neurological side effects. They are prescribed to temporarily relieve 
symptoms of metastatic brain tumors and only the lowest grade of recommendation 
can be made for mild to moderate symptoms. Higher doses may be recommended 
for patients with adverse symptoms tapered slowly over two weeks or longer. 
Sustained corticosteroid administration for long durations requires close monitor-
ing to prevent associated immediate side effects and complications occurring in 
the long term. Due to well-characterized complications developing in response to 
steroid therapy, a need for steroid-sparing drugs such as Bevacizumab arises, but it 
has its limitations. Currently, there is no standard dosing regimen recommended for 
corticosteroids and they are prescribed depending on individual needs to maximize 
symptomatic relief and minimize side effects. Therefore, to bring about positive 
patient outcomes and to potentially optimize the benefits of corticosteroid therapy, 
it is suggested that future studies should focus on appropriate dosing regimens and 
approaches to minimize the occurrence of side effects taking into consideration the 
risk factors that may negatively influence the medical state.
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